Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure | Zendy

Harald Lapp | Zendy; Veselin Mitrović | Zendy; Norbert Franz | Zendy; Kurt Huber | Zendy; Michael Buerke | Zendy; Judith Wolfertz | Zendy; Wolfgang Mueck | Zendy; Sigrun Unger | Zendy; Georg Wensing | Zendy; Reiner Frey | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Cinaciguat (BAY 58–2667) Improves Cardiopulmonary Hemodynamics in Patients With Acute Decompensated Heart Failure

Author(s) -

Harald Lapp,

Veselin Mitrović,

Norbert Franz,

Kurt Huber,

Michael Buerke,

Judith Wolfertz,

Wolfgang Mueck,

Sigrun Unger,

Georg Wensing,

Reiner Frey

Publication year - 2009

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.108.800292

Subject(s) - medicine , pulmonary wedge pressure , hemodynamics , vascular resistance , heart failure , tolerability , pulmonary artery , anesthesia , blood pressure , cardiology , acute decompensated heart failure , central venous pressure , cardiac output , heart rate , adverse effect

Cinaciguat (BAY 58-2667) is the first of a new class of soluble guanylate cyclase activators in clinical development for acute decompensated heart failure. We aimed to assess the hemodynamic effects, safety, and tolerability of intravenous cinaciguat in patients with acute decompensated heart failure (pulmonary capillary wedge pressure > or =18 mm Hg).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research